Clinical Trial Update: Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating the combination of Pyrotinib and Docetaxel in patients with HER2-positive advanced gastric cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: HER2 Positive Gastric Cancer | Phase 1 | Status: UNKNOWN